Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lacticaseibacillus paracasei PS23
- Development stage
- Preclinical
- Lead developer
- Bened Biomedical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lacticaseibacillus paracasei PS23 (PS23) is a specific probiotic strain, also known as a psychobiotic, developed by Bened Biomedical Co. Ltd. [13, 14]. It can be administered as a live probiotic (L-PS23) or a heat-treated postbiotic (HT-PS23). [20] The strain is being investigated for a wide range of therapeutic benefits, including anxiety reduction, sleep improvement, cognitive function, exercise performance, and ameliorating symptoms associated with aging, such as muscle loss and gastrointestinal dysfunction. [10, 13, 15] Clinical trials have demonstrated its efficacy in reducing anxiety and improving sleep in stressed individuals, as well as alleviating cognitive and physical symptoms of long COVID. [11, 13, 23] Its mechanism of action is believed to involve the modulation of the gut-brain axis, leading to balanced neurotransmitter levels (dopamine and serotonin), increased brain-derived neurotrophic factor (BDNF), and reduced cortisol. [15, 17] It also exhibits anti-inflammatory effects and has been shown to preserve mitochondrial function. [15, 17]
- Brand names
- PS23PS-23PS 23
- Other names
- Lactobacillus paracasei PS23
Beyond the preview
Go deeper on Lacticaseibacillus paracasei PS23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lacticaseibacillus paracasei PS23.